The US Congress expands requirements for pharmaceutical companies to file agreements with the FTC and DOJ

What occurred and why does it matter? President Trump on October 24 signed the SUPPORT for Patients and Communities Act (H.R. 6), which together with the Patient Right to Know Drug Prices Act (S. 2554), signed October 10, expands the scope of pharmaceutical product-related agreements subject to filing requirements under subtitle B of Title XI of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). Of particular note, parties to certain agreements regarding biosimilar applications now must file the agreements with the

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)

Citation

Krista Carver, Andrew D. Lazerow, Michael Stern, Kavita Pillai, The US Congress expands requirements for pharmaceutical companies to file agreements with the FTC and DOJ, 24 octobre 2018, e-Competitions October 2018, Art. N° 95617

Visites 32

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues